<DOC>
	<DOC>NCT03031691</DOC>
	<brief_summary>A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in Combination with Chemotherapy for Subjects with Previously Treated Metastatic Colorectal Cancer.</brief_summary>
	<brief_title>A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This is a phase 1b dose escalation study of the safety and pharmacodynamics of brontictuzumab in combination with chemotherapy for subjects with previously treated metastatic colorectal cancer. This study consists of a screening period, a treatment period and a post-treatment follow up period in which patients will be followed for survival for up to 24 months. Patients will be enrolled in two stages: a dose-escalation stage and an expansion phase. Approximately 34 patients will be enrolled in this study at approximately 5 study centers in the United States.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>Histologically confirmed metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine, oxaliplatin and irinotecanbased chemotherapy, an antiVEGF biological therapy, and if KRAS wildtype, an antiEGFR therapy ECOG performance status 0 or 1 Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors Subjects with known active HIV infection. Subjects with HIV that are under a stable antiretroviral regimen and have no evidence of immune deficiency (normal CD4 counts), undetectable viral load, and no HIVrelated infections are eligible Subjects with uncontrolled diarrhea &lt;30 days prior to first administration of study drug Subjects with any history of or current clinically significant gastrointestinal disease including, but not limited to: Inflammatory bowel disease (including ulcerative colitis and Crohn's disease) Active peptic ulcer disease Known intraluminal metastatic lesion(s) with risk of bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>